ADC Therapeutics SA (NYSE:ADCT) Holdings Boosted by Wellington Management Group LLP

Wellington Management Group LLP grew its stake in ADC Therapeutics SA (NYSE:ADCT - Free Report) by 50.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 253,342 shares of the company's stock after acquiring an additional 84,785 shares during the period. Wellington Management Group LLP owned about 0.26% of ADC Therapeutics worth $504,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. ProShare Advisors LLC increased its holdings in ADC Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 22,901 shares of the company's stock valued at $46,000 after buying an additional 7,535 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of ADC Therapeutics by 21.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,520 shares of the company's stock worth $93,000 after acquiring an additional 8,246 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of ADC Therapeutics by 122.6% in the 4th quarter. Russell Investments Group Ltd. now owns 16,794 shares of the company's stock valued at $33,000 after acquiring an additional 9,248 shares during the last quarter. SG Americas Securities LLC raised its position in shares of ADC Therapeutics by 35.6% during the 4th quarter. SG Americas Securities LLC now owns 36,140 shares of the company's stock worth $72,000 after acquiring an additional 9,483 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of ADC Therapeutics by 6.0% during the 4th quarter. Bank of New York Mellon Corp now owns 171,993 shares of the company's stock worth $342,000 after acquiring an additional 9,750 shares in the last quarter. 41.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $8.00 price objective on shares of ADC Therapeutics in a report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $8.00 price target on shares of ADC Therapeutics in a research report on Monday, March 31st. Stephens increased their price objective on ADC Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Cantor Fitzgerald restated an "overweight" rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Finally, Guggenheim reduced their price target on shares of ADC Therapeutics from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Monday, March 31st. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $7.75.

ADC Therapeutics Price Performance

NYSE:ADCT traded down $0.10 during trading hours on Monday, reaching $3.57. 757,801 shares of the company were exchanged, compared to its average volume of 619,318. The firm has a market cap of $354.07 million, a price-to-earnings ratio of -1.49 and a beta of 1.96. The stock has a 50 day simple moving average of $1.76 and a 200 day simple moving average of $1.82. ADC Therapeutics SA has a 52-week low of $1.05 and a 52-week high of $4.13.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.02. The firm had revenue of $23.03 million during the quarter, compared to analyst estimates of $17.71 million. On average, analysts predict that ADC Therapeutics SA will post -1.69 EPS for the current fiscal year.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.